RECQL and pancreatic adenocarcinoma: A polymorphism in RECQ1, A159C located in the 3′UTR, is associated with faster tumor progression and significantly reduced survival of pancreatic adenocarcinoma patients who received gemcitabine and radiotherapy [16].